Galderma stock climbs on strong Q1 Injectable Aesthetics performance

Shares in Galderma GALD.S rise 5.7% after the company posted Q1 results that beat expectations, driven by higher sales, especially in its Injectable Aesthetics division

Sales in Injectable Aesthetics were up 9.9% y/y, which analysts at Jefferies and J.P. Morgan point to as 6% above consensus, driven primarily by Neuromodulators sales

U.S. sales did not reach consensus expectations but this was offset by "pleasing double-digits" growth in international sales, Vontobel says

The U.S. sales launch of atopic dermatitis and prurigo nodularis medication Nemluvio was stronger than expected, analysts say, with Jefferies seeing the trajectory as "promising when compared to Sanofi SASY.PA/Regeneron's REGN.O Dupixent and Eli Lilly's LLY.N Ebglyss"

Up to the previous session's close, shares were down 19.9%​ YTD